Sarclisa Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing prevalence of multiple myeloma, advancements in monoclonal antibody development, expansion of oncology treatment centers, improved diagnostic capabilities for blood cancers, rising acceptance of biologic therapies.

The growth in the forecast period can be attributed to increasing investments in next-generation oncology drugs, growing focus on combination immunotherapies, expansion of personalized cancer treatment approaches, rising demand for targeted biologics, increasing regulatory approvals for novel myeloma therapies. Major trends in the forecast period include increasing adoption of cd38-targeted monoclonal antibody therapies, rising use of combination treatment regimens, growing focus on personalized oncology care, expansion of advanced biologics manufacturing capabilities, enhanced emphasis on treatment efficacy and safety.

The increasing prevalence of cancer is expected to drive the growth of the Sarclisa market going forward. Cancer is a group of diseases characterized by uncontrolled cell growth and division, which can invade surrounding tissues, spread to other parts of the body, and often form tumors or metastases, affecting various organs or systems. The rising prevalence of cancer is attributed to factors such as an aging population, lifestyle choices, environmental exposures, genetic predispositions, and improved detection methods that enhance diagnosis. Sarclisa is vital for treating cancer, particularly multiple myeloma, as it targets and eliminates malignant plasma cells, strengthening the immune system’s ability to combat the disease and improving treatment efficacy. For instance, in November 2024, PubMed, a US-based biomedical and life sciences literature database, reported that by 2050, 35.3 million cancer cases worldwide are expected, representing a 76.6% increase from the 2022 estimate of 20 million. Cancer-related deaths are projected to reach 18.5 million by 2050, an 89.7% increase from 9.7 million in 2022. Therefore, the increasing prevalence of cancer is driving the growth of the Sarclisa market.

The growing geriatric population is expected to propel the growth of the Sarclisa market. The geriatric population refers to adults aged 65 and older, who often face unique health, social, and economic challenges. The increase in this population is driven by longer life expectancy, advances in healthcare, and declining birth rates, contributing to global aging. Sarclisa provides an effective treatment for multiple myeloma in older adults, particularly those ineligible for intensive therapies like autologous stem cell transplants. For instance, in October 2024, the World Health Organization, a Switzerland-based intergovernmental organization, projected that by 2030, one in six people worldwide would be 60 years or older. By 2050, this population is expected to double to 2.1 billion. Therefore, the growing geriatric population is driving the growth of the Sarclisa market.

Major companies in the Sarclisa market are focusing on developing anti-CD38 monoclonal antibody therapies to meet the rising demand for effective first-line treatments for newly diagnosed multiple myeloma patients. Sarclisa (isatuximab) binds to CD38 receptors on multiple myeloma cells, inducing tumor cell death and modulating the immune response. Compared to traditional therapies, it offers targeted action and deeper responses when combined with standard-of-care regimens. For instance, in September 2024, Sanofi SA, a France-based pharmaceutical company, launched Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplant. This approval was supported by the IMROZ phase 3 study, demonstrating a 40% reduction in disease progression or death compared to VRd alone.

Major companies operating in the sarclisa market are Sanofi S.A.

North America was the largest region in the sarclisa market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sarclisa market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the sarclisa market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the sarclisa market by increasing costs associated with imported biologic manufacturing inputs, specialized laboratory equipment, cold-chain logistics components, and active pharmaceutical ingredients used in monoclonal antibody production. Oncology drug manufacturers and healthcare providers in North America and Europe are most affected due to reliance on global biologics supply chains, while Asia-Pacific faces higher production input costs. These tariffs are increasing overall treatment costs and affecting pricing strategies. However, they are also encouraging localized biologics manufacturing, regional supply chain diversification, and investments in domestic pharmaceutical production infrastructure.

The sarclisa market research report is one of a series of new reports that provides sarclisa market statistics, including sarclisa industry global market size, regional shares, competitors with a sarclisa market share, detailed sarclisa market segments, market trends and opportunities, and any further data you may need to thrive in the sarclisa industry. This sarclisa market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Sarclisa is a monoclonal antibody used to treat certain cancers, specifically multiple myeloma, a type of blood cancer. It works by targeting and binding to CD38, a protein present on the surface of multiple myeloma cells, helping the immune system identify and destroy these cancerous cells. It is often used in combination with other cancer therapies to enhance treatment outcomes.

The main formulations of Sarclisa include injectable solution and lyophilized powder for injection. It is indicated for relapsed or refractory multiple myeloma - where the disease returns after initial treatment or no longer responds to therapy - as well as for newly diagnosed multiple myeloma. The medication is distributed through hospital and retail pharmacies.

The sarclisa market consists of sales of chemotherapy agents, immunotherapy drugs, biosimilars, and diagnostic kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.